Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers Discover New Method to Treat Cancer

20.03.2003


Research at Oxford University’s Institute of Molecular Medicine has identified a novel therapeutic regimen for the treatment of cancer that provides significant advantages over the existing methods of cancer treatment.



There are already a number of regimens available for treatment of cancer, including chemotherapy, which is commonly used to treat a number of different types of cancer. In most cases chemotherapeutic agents are given at the maximum tolerated dose (MTD), but at such doses the treatments can only be given in short courses and often have unacceptable side effects. In recent years, the use of immunotherapy for tumours has also increased, but tumour cells have been shown to evade immunotherapy by mutating to avoid presentation of the specific tumour epitope to the immune system. It has previously been suggested that a combination of immunotherapy and chemotherapy may prove effective as a treatment. However, this has not proved ideal since conventional chemotherapy suppresses the immune system, thereby reducing the effectiveness of the immunotherapy.

Researchers in Oxford have now devised a novel therapeutic regimen that combines the advantages of both chemotherapy and immunotherapy whilst reducing the disadvantages of each. It has been shown that chemotherapeutic agents can have a beneficial effect at doses lower than the MTD (such a dosing regimen has become known as metronomic dosing). Metronomic dosing, whilst not being as aggressive as the MTD regimen, has fewer side effects and can be used for longer periods without a break. The researchers have identified a metronomic regimen that does not cause the severe immunosuppression of standard chemotherapy and so opens the possibility of combining immunotherapy and chemotherapy. Furthermore, they have shown that such a combination therapy is more effective at inhibiting tumour growth than either chemotherapy (at MTD or as a metronomic dose), or immunotherapy alone or than immunotherapy in combination with chemotherapy at MTD.


Isis Innovation, Oxford University’s technology transfer company, has filed a patent on this exciting Oxford discovery. Companies interested in product developments arising from this work are invited to contact Isis to discuss how they could utilise this technology.

Jennifer Johnson | alfa
Further information:
http://www.isis-innovation.com/licensing/1194.html

More articles from Health and Medicine:

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>